GENFIT : to participate at the BIO International Convention in Boston on June 18-21, 2012
06/13/2012| 02:06pm US/Eastern
Recommend:
Press Release
Communiqué de Presse
GENFIT TO PARTICIPATE AT THE BIO INTERNATIONAL
www . genfit . com
CONVENTION IN BOSTON ON JUNE 18-21, 2012
Lille (France), Cambridge (Massachusetts, United States),
June 12, 2012 - GENFIT (Alternext: ALGFT; ISIN:
FR0004163111), a biopharmaceutical company at the forefront
of drug discovery and development, focusing on the early
diagnosis and preventive treatment of cardiometabolic and
associated disorders, today announces its participation at
the BIO International Convention taking place at the Boston
Convention & Exhibition Center (BCEC) on June 18-21,
2012.
The BIO International Convention is an
internationally-renowned biotechnology conference and
represents a unique opportunity to meet industrials,
scientific experts, and investors, and to create new
partnerships. The Company will be represented at this meeting
by Jean-François Mouney, co-founder and CEO, and Dr. Dean W.
Hum, CSO.
« The positive results obtained since the beginning of the
year for GFT505, our leading drug candidate, as well as the
recent progress on our other proprietary research programs,
have generated a strong interest within the pharmaceutical
industry. We thus hope that the numerous meetings planned at
BIO will yield productive discussions. » declared Dr. Karine
Bertrand, EVP Corporate Business Development.
About GENFIT:
GENFIT is a biopharmaceutical company focused on the
Discovery and Development of drug candidates in therapeutic
fields linked to cardiometabolic disorders
(prediabetes/diabetes, atherosclerosis, dyslipidemia,
inflammatory diseases…). GENFIT uses a multi-pronged approach
based on early diagnosis, preventive solutions, and
therapeutic treatments and advances therapeutic research
programs, either independently or in partnership with leading
pharmaceutical companies, including Sanofi, to address these
major public health concerns and their unmet medical
needs.
GENFIT's research programs have resulted in the creation of a
rich and diversified pipeline of drug candidates at different
stages of development, including GENFIT's lead proprietary
compound, GFT505, that is currently in Phase II.
With facilities in Lille, France, and Cambridge, MA (USA),
the Company has approximately 100 employees. GENFIT is a
public company listed on the Alternext trading market by
Euronext™ Paris (Alternext: ALGFT; ISIN: FR0004163111). www.genfit.com
Contacts:
GENFIT
Jean-François Mouney - CEO & Chairman of the Management
Board
Ph. +333 2016 4000
MILESTONES - Press Relations
Bruno Arabian
Ph. +33 1 7544 8740 / +336 8788 4726 - barabian@milestones.fr
Items in this press release may contain forward-looking
statements involving risks and uncertainties. The Company's
actual results could differ substantially from those an
ticipated in these statements owing to various risk factors
which are described in the Company's prospectus. This press
release has been prepared in both French and English
languages. In the event of any differences between the two
texts, the French language version shall
supersede.
[1]
distributed by
|
|
Recommend :
